Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Viruses with RNA Genomes01:29

Viruses with RNA Genomes

34
RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
34
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

46.0K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
46.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of efficacy of intra-articular injection of platelet-rich plasma with bupivacaine and steroid combination in chronic shoulder pain.

Journal of anaesthesiology, clinical pharmacology·2026
Same author

Redox regulation of glutamate-1-semialdehyde aminotransferase modulates the synthesis of 5-aminolevulinic acid in Arabidopsis.

Frontiers in plant science·2025
Same author

Viral helicase and methyltransferase promote genotype one-hepatitis e virus internal ribosome entry site-like element activity.

Npj viruses·2025
Same author

Evaluation of immune response in BALB/c mice generated by SARS-CoV-2 membrane-envelope virus-like particles.

International journal of biological macromolecules·2025
Same author

Comparison of radiofrequency ablation of genicular nerve with genicular nerve block in patients with osteoarthritis of the knee.

Journal of anaesthesiology, clinical pharmacology·2025
Same author

Reply to: In Response to Fuller et al., Functional Rating Scale 2.0 (FuRST 2.0): A patient-reported outcome measure of function for Huntington's disease.

Journal of Huntington's disease·2025

Related Experiment Video

Updated: Jul 11, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.1K

Inhibition of HEV Replication by FDA-Approved RdRp Inhibitors.

Preeti Hooda1, Mohammed Al-Dosari2, Neha Sinha3

  • 1Virology Lab, Department of Life Sciences, Shiv Nadar Institute of Eminence, Gautam Budh Nagar 201314, India.

ACS Omega
|November 16, 2023
PubMed
Summary
This summary is machine-generated.

Favipiravir and sofosbuvir show promise in treating Hepatitis E virus (HEV) infection by inhibiting viral RNA-dependent RNA polymerase. Combination therapy significantly reduced viral RNA, suggesting favipiravir is a potential anti-HEV drug.

More Related Videos

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

9.8K
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

17.9K

Related Experiment Videos

Last Updated: Jul 11, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.1K
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

9.8K
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

17.9K

Area of Science:

  • Virology
  • Hepatology
  • Drug Discovery

Background:

  • Hepatitis E virus (HEV) causes acute and chronic hepatitis, with limited treatment options for chronic cases.
  • Current treatments for chronic HEV include pegylated interferon-α and ribavirin.
  • Viral RNA-dependent RNA polymerase (RdRp) is crucial for HEV replication and a potential antiviral target.

Purpose of the Study:

  • To screen known RNA-dependent RNA polymerase (RdRp) inhibitor molecules for anti-HEV activity.
  • To evaluate the efficacy of favipiravir and sofosbuvir as monotherapy and combination therapy against HEV.
  • To identify promising antiviral agents for Hepatitis E treatment.

Main Methods:

  • Screening of RdRp inhibitors: favipiravir, sofosbuvir, remdesivir, filibuvir, and tegobuvir.
  • In vitro assessment of RdRp inhibitory activity (IC50 values) for selected compounds.
  • Evaluation of combination therapy efficacy by measuring viral RNA copy numbers.

Main Results:

  • Favipiravir and sofosbuvir demonstrated significant inhibition of HEV RdRp activity, with IC50 values of 10.2 ± 4.9 μM and 5.2 ± 2.9 μM, respectively.
  • Ribavirin served as a reference drug with an IC50 of 3.5 ± 1.6 μM.
  • Combination therapy with favipiravir and sofosbuvir reduced viral RNA copy numbers by approximately 90%, indicating an additive effect.

Conclusions:

  • Favipiravir and sofosbuvir are effective inhibitors of HEV RdRp.
  • Combination therapy of favipiravir and sofosbuvir shows significant potential for treating Hepatitis E.
  • Favipiravir is a promising candidate for further development as an anti-HEV therapeutic agent, particularly in combination regimens.